Investigational Drug Information for Pa-824
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Pa-824?
Pa-824 is an investigational drug.
There have been 25 clinical trials for Pa-824.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and Tuberculosis, Multidrug-Resistant. The leading clinical trial sponsors are Global Alliance for TB Drug Development, Ministry of Public Health, Republic of Belarus, and National Institute of Allergy and Infectious Diseases (NIAID).
There are twenty-five US patents protecting this investigational drug and one hundred and eighty-eight international patents.
Summary for Pa-824
| US Patents | 25 |
| International Patents | 188 |
| US Patent Applications | 114 |
| WIPO Patent Applications | 96 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2015-02-01) |
| Vendors | 65 |
Recent Clinical Trials for Pa-824
| Title | Sponsor | Phase |
|---|---|---|
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM) | Global Alliance for TB Drug Development | Phase 2 |
| Economic Evaluation of New MDR TB Regimens | Clinical HIV Reserach Unit, Wits Health Consortium | Phase 2/Phase 3 |
| Economic Evaluation of New MDR TB Regimens | Liverpool School of Tropical Medicine | Phase 2/Phase 3 |
Clinical Trial Summary for Pa-824
Top disease conditions for Pa-824
Top clinical trial sponsors for Pa-824
US Patents for Pa-824
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pa-824 | See Plans and Pricing | Multi-drug therapies for tuberculosis treatment | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| Pa-824 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Pa-824 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Pa-824 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Pa-824 | See Plans and Pricing | Isothermal methods for amplifying nucleic acid samples | Tangen Biosciences, Inc. (Branford, CT) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pa-824
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pa-824 | China | CN107249691 | 2034-11-03 | See Plans and Pricing |
| Pa-824 | European Patent Office | EP3215225 | 2034-11-03 | See Plans and Pricing |
| Pa-824 | Japan | JP2017533220 | 2034-11-03 | See Plans and Pricing |
| Pa-824 | World Intellectual Property Organization (WIPO) | WO2016073524 | 2034-11-03 | See Plans and Pricing |
| Pa-824 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
